Progress Towards Developing an Effective HIV Cure

Steven G. Deeks, MD
Professor of Medicine
University of California, San Francisco

CME VIDEOTop of page

About the Presenter:Top of page

Steve Deeks is a recognized expert on HIV-associated immune dysfunction and its impact on HIV persistence (the “reservoir”) and health during antiretroviral therapy. He has published over 500 peer-review articles, editorials and invited reviews. He has been the recipient of several NIH grants, including an NIH-funded international collaboratory aimed at developing therapeutic interventions to cure HIV infection. In March, 2020, created the “Long-term Impact of Infection with Novel Coronavirus (LIINC)” cohort, now supporting dozens of studies addressing the impact of SARS-CoV-2.

Learning Objectives: Top of page

At the completion of this educational session, learners will:

  • Discuss why a cure may be needed from an individual and public health perspective.
  • Outline the major causes of HIV persistence during therapy.
  • Summarize novel therapeutic interventions that are being studied or considered as curative strategies.
  • Describe the emerging role of gene modification approaches in HIV cure research.

CME Information:Top of page

This CME activity has approved for AMA PRA Category 1 Credit™ for October 14, 2020 as a live activity.  This activity will also be available as an enduring activity from October 15, 2020, through October 13, 2023.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity. - Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose. - Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose. - Dr. Steven G. Deeks (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Research support from Gilead, and Merck; Scientific advisory board with Enochian Biosciences; Ad hoc consultant with AbbVie. Dr. Deeks will support his presentation and clinical recommendations with the best available evidence from the medical literature and will submit his slides in advance for adequate peer review.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from: Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Evaluation

You must be logged in to post a comment. Login | Register